Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7507062 in systemic lupus erythematosus
NL-OMON60252Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of RO7507062 in systemic lupus erythematosus (SLE), sponsored by Roche. Primary endpoint: Primary endpoint(s). Started Oct 2023; status: completed.
02
Drugs
RO7507062
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60252.